LDLR and familial hyperaldosteronism: Based on the CBE system and pooled screening, we established a novel strategy for large-scale screening of LDLR LOF mutations, obtaining hundreds of LDLR pathogenic point mutations, so that some potential FH patients can be diagnosed by early gene screening.